前列腺癌患者PSMA高摄取肋骨病灶:鉴别假阳性与转移性疾病
本研究纳入2021至2023年接受[18F]F-DCFPyL PET/CT检查且存在PSMA高摄取肋骨病灶的175例前列腺癌患者,以病理、系列影像和临床评估作为复合参考标准判断肋骨病灶病因。47/175(26.9%)为肋骨转移,其中仅1/47(2.1%)无其他部位PSMA高摄取转移灶;转移灶SUVmax和miPSMA评分更高、更常累及多根肋骨且更常呈硬化性,溶骨/骨折仅见于良性病灶。
要点
- 无其他部位PSMA高摄取转移证据时,孤立性PSMA高摄取肋骨病灶几乎均为良性。
- 转移性肋骨病灶SUVmax和miPSMA评分更高,更常累及多根肋骨且更常呈硬化性。
- 溶骨性改变或骨折仅见于良性肋骨病灶。
核心结论
- PSMA高摄取转移性与良性肋骨病灶在多项影像和临床病理因素上存在差异;无其他部位转移的孤立性肋骨病灶几乎均为良性,仔细评估CT特征有助于诊断良性病灶。
研究设计与样本
- 连续纳入2021至2023年因新诊断中高危前列腺癌或复发/转移性疾病接受[18F]F-DCFPyL PET/CT且存在PSMA高摄取肋骨病灶的前列腺癌患者175例(中位年龄71岁,IQR 65-77),以基于病理、系列影像和临床评估的复合参考标准判断肋骨病灶病因(转移性与非转移性)。
关键影像表现/征象
- 转移性肋骨病灶SUVmax和miPSMA评分更高(p < 0.01)。
- 转移性肋骨病灶更常累及多根肋骨(p < 0.01)。
- 转移性肋骨病灶更常呈硬化性(p < 0.01)。
- 溶骨性改变或骨折仅见于良性病灶。
- 47/175(26.9%)患者存在肋骨转移,其中仅1/47(2.1%)无其他部位PSMA高摄取转移灶,其余46/47(97.9%)同时存在其他部位PSMA高摄取病灶。
诊断标准与关键数值
- 肋骨转移患者年龄更大、前列腺特异性抗原水平更高且肿瘤分级更高(p < 0.01)。
- 转移性肋骨病灶SUVmax和miPSMA评分更高、更常累及多根肋骨且更常呈硬化性(p < 0.01);溶骨性改变或骨折仅见于良性病灶。
- 无其他部位PSMA高摄取转移证据的孤立性肋骨病灶几乎均为良性(仅1/47即2.1%的肋骨转移患者为孤立性肋骨转移)。
临床应用与阅片要点
- 阅片时需结合有无其他部位PSMA高摄取转移灶判断肋骨病灶性质,孤立性肋骨病灶几乎均为良性。
- 仔细评估CT特征(硬化、溶骨、骨折、无对应结构异常)有助于鉴别良恶性PSMA高摄取肋骨病灶。
- 转移性肋骨病灶多表现为SUVmax和miPSMA评分较高、累及多根肋骨且呈硬化性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Prostate-specific membrane antigen (PSMA)-PET/CT has become integral to management of prostate cancer; however, PSMA-avid rib lesions pose a diagnostic challenge. This study investigated clinicopathological and imaging findings that predict metastatic etiology of PSMA-avid rib lesions.
MATERIALS AND METHODS: Consecutive patients with prostate cancer that underwent PET/CT with [18F]F-DCFPyL in 2021-2023 for newly diagnosed intermediate-/high-risk prostate cancer or recurrent/metastatic disease and had PSMA-avid rib lesions were included. Imaging findings assessed were: lesion number, PSMA expression (maximum standard uptake value (SUVmax), miPSMA score), CT features (sclerotic, lucent, fracture, no correlate), other sites of metastases, and primary tumor findings. A composite reference standard for rib lesion etiology (metastatic vs non-metastatic) based on histopathology, serial imaging, and clinical assessment was used.
RESULTS: One hundred and seventy-five men (median 71 years, IQR 65-77) with PSMA-avid rib lesions were included; 47/175 (26.9%) had rib metastases. Only 1/47 (2.1%) of these patients had isolated rib metastasis without PSMA-avid metastases in other bones, nodes, or visceral organs; the other 46/47 (97.9%) patients with rib metastases also had other sites of PSMA-avid disease. Patients with rib metastases were older, had higher prostate-specific antigen levels, and higher-grade tumors (p < 0.01). Metastatic rib lesions had higher uptake (SUVmax, miPSMA), more commonly involved multiple ribs, and were more often sclerotic (p < 0.01); lucency/fractures were only seen in benign lesions.
CONCLUSION: Several imaging and clinicopathological factors differed between PSMA-avid metastatic and benign lesions. Isolated rib lesions without other sites of metastasis are almost always benign. Careful assessment of CT features can help diagnose benign lesions.
KEY POINTS: Question While prostate-specific membrane antigen (PSMA)-PET/CT has become integral to the management of prostate cancer, PSMA-avid rib lesions pose a diagnostic challenge. Findings Approximately a quarter of patients who had PSMA-avid rib lesions were metastatic. However, only 2.1% of them had isolated rib metastasis (without PSMA-avid metastases elsewhere). Clinical relevance Isolated PSMA-avid rib lesions are almost always benign when there is no evidence of metastatic disease elsewhere. Scrutinizing CT features can help diagnose benign PSMA-avid lesions with greater certainty.
引用
- Woo S, Becker AS, Leithner D, et al. PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease. Eur Radiol. 2025. PMID: 40108014. doi:10.1007/s00330-025-11514-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。